SCHEMBL3389545

SCHEMBL3389545

C1=NC(c2ccccc2)CCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 2/20 0.46
NOS2 P35228 2/20 0.46
SLC18A3 Q16572 1/20 0.39
TAAR1 Q96RJ0 3/20 0.36
MAOB P27338 8/20 0.35
MAOA P21397 7/20 0.35
KDM1A O60341 5/20 0.35
CYP2C19 P33261 4/20 0.35
CYP2B6 P20813 3/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2D6 P10635 2/20 0.35
CYP2C9 P11712 2/20 0.35
LMNA P02545 2/20 0.35
CYP3A4 P08684 1/20 0.35
HTR1A P08908 1/20 0.35
ADRA2A P08913 1/20 0.35
CYP2A6 P11509 1/20 0.35
SLC6A2 P23975 1/20 0.35
HTR2C P28335 1/20 0.35
ADRA1A P35348 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7068812 0.87 NOS1 (0.40) NOS1NOS2SLC18A3TAAR1MAOB
Hydrochloric Acid SCHEMBL6210524 0.80 CYP1A2 (0.36) NOS1NOS2CYP2C19CYP1A2CYP3A4
SCHEMBL999273 0.80 NOS1 (0.30) NOS1NOS2
Hydrochloric Acid SCHEMBL1566698 0.78 CYP11B2 (0.50) CYP2C19CYP1A2CYP2D6CYP2C9LMNA
SCHEMBL7609774 0.76 KDM1A (0.46) NOS1NOS2TAAR1MAOBKDM1A
SCHEMBL290575 0.73 TAAR1 (0.42) TAAR1MAOBMAOAKDM1ALMNA
SCHEMBL7416327 0.73 ADORA2B (0.32)
SCHEMBL10622601 0.73 NOS1 (0.52) NOS1NOS2SLC18A3TAAR1MAOB
SCHEMBL11313922 0.72 HTR2C (0.41) MAOBLMNAHTR2CDRD3SLC6A3
SCHEMBL7688066 0.72 MAOA (0.35) MAOBMAOAKDM1ASLC6A2HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0254623-B1 AMINOALKYLTHIO TRIAZOLOPYRIDINE OR TRIAZOLOQUINOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, MEDICAMENTS CONTAINING THEM, PARTICULARLY USEFUL AS ANTALGICS LABORATOIRES UPSA (FR) 1993-06-09 EP claimed
EP-0254623-A1 Aminoalkylthio triazolopyridine or triazoloquinoline derivatives, process for their preparation, medicaments containing them, particularly useful as antalgics LABORATOIRES UPSA (FR) 1988-01-27 EP claimed
US-10074813-B2 Organic semiconductor composition and method for manufacturing organic semiconductor element FUJIFILM CORPORATION (JP) 2018-09-11 US disclosed
US-9878986-B2 Compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2018-01-30 US disclosed
CN-105358556-B New compound for selective histone deacetylase inhibitor and the pharmaceutical composition comprising it 株式会社钟根堂 2018-01-02 CN disclosed
EP-3242339-A1 ORGANIC SEMICONDUCTOR COMPOSITION AND METHOD FOR MANUFACTURING ORGANIC SEMICONDUCTOR ELEMENT Fujifilm Corporation (JP) 2017-11-08 EP disclosed
US-20170317296-A1 ORGANIC SEMICONDUCTOR COMPOSITION AND METHOD FOR MANUFACTURING ORGANIC SEMICONDUCTOR ELEMENT FUJIFILM CORPORATION (JP) 2017-11-02 US disclosed
US-20170152230-A9 NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2017-06-01 US disclosed
US-20160083354-A1 NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARM CORP (KR) 2016-03-24 US disclosed
EP-2991982-A1 NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Chong Kun Dang Pharmaceutical Corp. (KR) 2016-03-09 EP disclosed
CN-105358556-A Novel compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same CHONG KUN DANG PHARM CORP 2016-02-24 CN disclosed
US-6673795-B2 SUCH AS 6-(4-(4-FLUORO-PHENYL)-PIPERAZIN-1-YL)-2-METHYL-5-NITRO-3-(2,2,2-TRIFLUORO -ETHYL)-3H-PYRIMIDIN-4-ONE, WHICH ARE METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS USEFUL IN TREATING PSYCHOLOGICAL DISORDERS HOFFMANN-LA ROCHE INC. 2004-01-06 US disclosed
US-20030060466-A1 Pyrimidine, pyrazine and triazine derivatives F. HOFFMANN-LA ROCHE AG (CH) 2003-03-27 US disclosed
WO-2002098864-A1 PYRIMIDINE, TRIAZINE AND PYRAZINE DERIVATIVES AS GLUTAMATE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2002-12-12 WO disclosed
EP-0254623-B1 AMINOALKYLTHIO TRIAZOLOPYRIDINE OR TRIAZOLOQUINOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, MEDICAMENTS CONTAINING THEM, PARTICULARLY USEFUL AS ANTALGICS LABORATOIRES UPSA (FR) 1993-06-09 EP disclosed
US-4886805-A Novel aminoalkylthio derivatives of triazolopyridine or triazoloquinoline, the processes for their preparation, and drugs, useful especially as analgesics, in which they are present Centre D'Activite Et De Recherches Pharmaceutique Industrielle Biologique Medicale (FR) 1989-12-12 US disclosed
US-4886805-A Novel aminoalkylthio derivatives of triazolopyridine or triazoloquinoline, the processes for their preparation, and drugs, useful especially as analgesics, in which they are present Centre D'Activite Et De Recherches Pharmaceutique Industrielle Biologique Medicale (FR) 1989-12-12 US disclosed
EP-0254623-A1 Aminoalkylthio triazolopyridine or triazoloquinoline derivatives, process for their preparation, medicaments containing them, particularly useful as antalgics LABORATOIRES UPSA (FR) 1988-01-27 EP disclosed
EP-0007067-A1 Phenylpiperidine derivatives, processes for their preparation and pharmaceutical compositions containing them CIBA-GEIGY AG (CH) 1980-01-23 EP disclosed
US-3995045-A ANTIINFLAMMATORY AGENTS E. R. SQUIBB & SONS, INC. (US) 1976-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10074813-B2 Organic semiconductor composition and method for manufacturing organic semiconductor element OR10J3, NR0B1, NR1H3 NOS1 407/4885NOS2 1084/4885SLC18A3 3055/4885
US-20160083354-A1 NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HDAC1, HDAC5, HDAC4 NOS1 1462/4885NOS2 1623/4885SLC18A3 3977/4885
US-20170152230-A9 NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HDAC1, HDAC5, HDAC4 NOS1 1462/4885NOS2 1623/4885SLC18A3 3977/4885
US-20030060466-A1 Pyrimidine, pyrazine and triazine derivatives P2RX5, IL5, P2RX2 NOS1 3490/4885NOS2 3739/4885SLC18A3 3043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.